Corporate Events

ReEir, Inc. announced that it has received ¥580 million in a round of funding on July 17, 2025. The transaction included participation from returning investors, Seibu Shinkin Capital Corporation, Hisamitsu Pharmaceutical Co., Inc., 01Booster Capital, new investors, TOPPAN Holdings Inc. Business Partners' Shareholding Association, Asahi Group Japan, Ltd., Sakurajyuji Co., Ltd., Izul Inc. and others. The funding round was conducted through a third-party allotment of shares. The company has raised ¥685 million in total funding till date.

The Board of Directors of Hisamitsu Pharmaceutical Co., Inc. has authorized a buyback plan on July 10, 2025.

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces a share repurchase program. Under the program, the company will repurchase 3,000,000 shares, representing 4.09% of its issued share capital, for ¥15,000 million.. The purpose of the program is to enhance sustainable value for the company and its shareholders. The repurchased shares will be cancelled. The program will run unit December 31, 2025. As of June 30, 2025, the company had 73,402,370 shares issued (excluding treasury stock) and 1,762,525 shares in treasury.

Hisamitsu Pharmaceutical Co., Inc. provided consolidated earnings guidance for the fiscal year ending February 28, 2026. For the period, the company expected net sales of JPY 165,000 million, operating profit of JPY 20,000 million, profit attributable to owners of parent of JPY 22,000 million and profit per share of JPY 301.45.

Hisamitsu Pharmaceutical Co., Inc., Board Meeting, Jul 10, 2025. Agenda: To consider subscription requirements for stock acquisition rights to be issued as stock compensation-type stock options to the Company's directors (excluding outside directors); and to consider soliciting subscribers for the said stock acquisition rights etc.

Hisamitsu Pharmaceutical Co., Inc. at the 123rd annual general meeting of shareholders held May 22, 2025 have resolved the appointments of directors and corporate auditors as follows, effective on May 22, 2025. The appointments of directors include NAKATOMI, Kazuhide as President and CEO; SAITO, Kyu as Managing Director, Executive Officer; TSUTSUMI, Nobuo as Director, Executive Officer; MURAYAMA, Shinichi as Director, Executive Officer; TAKIYAMA, Koji as Director, Executive Officer; and ISOBE, Yuichi who has been newly appointed as Director, Executive Officer. Additionally, ANZAI, Yuichiro serves as an Outside Director (part-time); MATSUO, Tetsugo is also an Outside Director (part-time); WATANABE, Tamako holds the position of Outside Director (part-time); and NOGUCHI, Midori has been newly appointed as an Outside Director (part-time).

Hisamitsu Pharmaceutical Co., Inc., Board Meeting, May 22, 2025. Agenda: To resolve to cancel treasury shares in accordance with the provisions of Article 178 of the Companies Act.

Hisamitsu Pharmaceutical Co., Inc. announced Exiting of Sugiyama, Kosuke as director.

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 22, 2025, at 10:00 Tokyo Standard Time. Location: 408 Tashiro Daikan-machi, Tosu, Saga, Japan Saga Japan Agenda: To consider matters regarding share acquisition rights, etc. of the company, status of independent auditor, and structure and policy of the company in the business report; to consider consolidated statements of changes in shareholders' equity and notes to consolidated financial statements in the consolidated financial statements; to consider non-consolidated statement of changes in shareholders' equity and notes to non-consolidated financial statements in the non-consolidated financial statements; to consider the business report, consolidated financial statements and non-consolidated financial statements for the company's 123rd fiscal year from March 1, 2024 to February 28, 2025; and to consider results of audits by the independent auditor and the board of corporate auditors of the consolidated financial statements for the company's 123rd fiscal year.

Hisamitsu Pharmaceutical Co., Inc. announced dividend for the fiscal year ended February 28, 2025. For the period, the company announced dividend of JPY 43 per share for the year-end against JPY 42.5 per share paid a year ago. Scheduled date of dividend payment: May 23, 2025. For the second quarter of fiscal year ending February 28, 2026, the company dividend forecast of JPY 45 per share against JPY 43 per share paid a year ago. For the fiscal year ending February 28, 2026, the company expects dividend to be JPY 45 per share against JPY 43 per share paid a year ago.

Hisamitsu Pharmaceutical Co., Inc. announced commemorative dividend forecast of ¥30.00 per share for the fiscal year ending February 28, 2026.

Hisamitsu Pharmaceutical Co., Inc. provided consolidated earnings guidance for the fiscal year ending February 28, 2026. For the period, the company expected net sales of JPY 165,000 million, operating profit of JPY 20,000 million, profit attributable to owners of parent of JPY 22,000 million and profit per share of JPY 298.86.

Hisamitsu Pharmaceutical Co., Inc., Board Meeting, Apr 10, 2025. Agenda: To consider appointment of candidates for directors & Exiting director.

Hisamitsu Pharmaceutical Co., Inc. announced that they will report Q1, 2026 results on Jul 10, 2025

Hisamitsu Pharmaceutical Co., Inc., 2025 Earnings Call, Apr 10, 2025

Hisamitsu Pharmaceutical Co., Inc., Q1 2026 Earnings Call, Jul 10, 2025

ORPHE Inc. announced that it has raised in an equity round of funding on March 27, 2025. The transaction included the participation from new investors Hisamitsu Pharmaceutical Co., Inc. and Q's Fix, K.K. The company will issue the shares through third-party allotment of new shares method.

Hisamitsu Pharmaceutical Co., Inc. announced that they will report fiscal year 2025 results on Apr 10, 2025

Hisamitsu Pharmaceutical Co., Inc. announced commemorative dividend of ¥4.00 per share for the fiscal year ending February 28, 2025.

Hisamitsu Pharmaceutical Co., Inc. revised consolidated earnings guidance for the fiscal year ending February 28, 2025. For the period, the company expected net sales of JPY 154,000 million, operating profit of JPY 18,000 million, profit attributable to owners of parent of JPY 20,500 million and profit per share of JPY 277.66.

Hisamitsu Pharmaceutical Co., Inc., Q3 2025 Earnings Call, Jan 09, 2025

ReEir, Inc. announced that it has received round of funding on December 9, 2024. The transaction included the participation from new invetsor Hisamitsu Pharmaceutical Co., Inc. The company will issue the shares through third-party allotment of method.

Hisamitsu Pharmaceutical Co., Inc. announced that they will report Q3, 2025 results on Jan 09, 2025

Hisamitsu Pharmaceutical Co., Inc., ¥ 43.0, Cash Dividend, Feb-27-2025

Hisamitsu Pharmaceutical Co., Inc., ¥ 2.00, Cash Dividend, Feb-27-2025

Hisamitsu Pharmaceutical Co., Inc. expected to report Q3 2025 results on January 10, 2025. This event was calculated by S&P Global (Created on October 10, 2024).

Hisamitsu Pharmaceutical Co., Inc., ¥ 2.00, Cash Dividend, Aug-29-2024